Belite Bio: Interesting Science, But Quite A Few Worries
Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.
Merck readies new Keytruda version ahead of major regulatory headwinds
Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...